JP2022141835A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022141835A5 JP2022141835A5 JP2022115300A JP2022115300A JP2022141835A5 JP 2022141835 A5 JP2022141835 A5 JP 2022141835A5 JP 2022115300 A JP2022115300 A JP 2022115300A JP 2022115300 A JP2022115300 A JP 2022115300A JP 2022141835 A5 JP2022141835 A5 JP 2022141835A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- group
- acceptable salt
- methyl
- following formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 229910052731 fluorine Inorganic materials 0.000 claims 10
- 125000001153 fluoro group Chemical group F* 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 108091000080 Phosphotransferase Proteins 0.000 claims 3
- 102000001253 Protein Kinase Human genes 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102000020233 phosphotransferase Human genes 0.000 claims 3
- 108060006633 protein kinase Proteins 0.000 claims 3
- MTAKGVHNFCQHBU-UHFFFAOYSA-N 2-(3-fluorophenyl)-2-hydroxyacetamide Chemical compound NC(=O)C(O)C1=CC=CC(F)=C1 MTAKGVHNFCQHBU-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382207 | 2017-04-18 | ||
| EP17382207.3 | 2017-04-18 | ||
| JP2019556703A JP7110232B2 (ja) | 2017-04-18 | 2018-04-11 | フェニル－２－ヒドロキシ－アセチルアミノ－２－メチル－フェニル化合物 |
| PCT/US2018/027005 WO2018194885A1 (en) | 2017-04-18 | 2018-04-11 | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556703A Division JP7110232B2 (ja) | 2017-04-18 | 2018-04-11 | フェニル－２－ヒドロキシ－アセチルアミノ－２－メチル－フェニル化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022141835A JP2022141835A (ja) | 2022-09-29 |
| JP2022141835A5 true JP2022141835A5 (https=) | 2022-10-26 |
| JP7331212B2 JP7331212B2 (ja) | 2023-08-22 |
Family
ID=58606227
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556703A Active JP7110232B2 (ja) | 2017-04-18 | 2018-04-11 | フェニル－２－ヒドロキシ－アセチルアミノ－２－メチル－フェニル化合物 |
| JP2022115300A Active JP7331212B2 (ja) | 2017-04-18 | 2022-07-20 | フェニル－２－ヒドロキシ－アセチルアミノ－２－メチル－フェニル化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556703A Active JP7110232B2 (ja) | 2017-04-18 | 2018-04-11 | フェニル－２－ヒドロキシ－アセチルアミノ－２－メチル－フェニル化合物 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11655214B2 (https=) |
| EP (2) | EP4039675B1 (https=) |
| JP (2) | JP7110232B2 (https=) |
| KR (2) | KR102575246B1 (https=) |
| CN (2) | CN117510405A (https=) |
| AU (2) | AU2018255191B2 (https=) |
| BR (1) | BR112019021867A2 (https=) |
| CO (1) | CO2019012767A2 (https=) |
| CR (1) | CR20190519A (https=) |
| CY (1) | CY1125150T1 (https=) |
| DK (2) | DK4039675T3 (https=) |
| ES (2) | ES2988739T3 (https=) |
| FI (1) | FI4039675T3 (https=) |
| HR (2) | HRP20220263T1 (https=) |
| HU (2) | HUE057745T2 (https=) |
| IL (2) | IL270005B (https=) |
| LT (2) | LT3612519T (https=) |
| MX (2) | MX389724B (https=) |
| MY (1) | MY199442A (https=) |
| NZ (1) | NZ758291A (https=) |
| PH (1) | PH12019502363B1 (https=) |
| PL (2) | PL4039675T3 (https=) |
| PT (2) | PT4039675T (https=) |
| RS (2) | RS65914B1 (https=) |
| SA (1) | SA519410320B1 (https=) |
| SG (1) | SG11201909680UA (https=) |
| SI (2) | SI4039675T1 (https=) |
| SM (2) | SMT202400357T1 (https=) |
| WO (1) | WO2018194885A1 (https=) |
| ZA (1) | ZA201906811B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4039675T3 (pl) | 2017-04-18 | 2025-01-07 | Eli Lilly And Company | Związki fenylo-2-hydroksyacetyloamino-2-metylo-fenylowe |
| US20210121527A1 (en) * | 2018-03-26 | 2021-04-29 | Icahn School Of Medicine At Mount Sinai | Methods of treating minimal residual cancer |
| EP4021893A1 (en) * | 2019-08-29 | 2022-07-06 | Hibercell, Inc. | Perk inhibiting compounds |
| US20220356186A1 (en) * | 2019-08-29 | 2022-11-10 | Hibercell, Inc. | Perk inhibiting pyrrolopyrimidine compounds |
| WO2021041976A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting indolinyl compounds |
| US12331054B2 (en) | 2019-08-29 | 2025-06-17 | Hibercell, Inc. | Perk inhibiting imidazolopyrazine compounds |
| WO2021231788A1 (en) * | 2020-05-13 | 2021-11-18 | Hibercell, Inc. | Perk inhibiting pyrrolopyrimidine compounds to treat viral infections |
| WO2021231782A1 (en) * | 2020-05-13 | 2021-11-18 | Hibercell, Inc. | Perk inhibitors for treating viral infections |
| CN113234029B (zh) * | 2021-05-25 | 2022-03-22 | 白银康寓信生物科技有限公司 | 一种2-氨基-3,5-二卤代吡嗪的合成方法 |
| AU2024242199A1 (en) * | 2023-03-30 | 2025-10-30 | Hibercell, Inc. | Crystalline forms of (r)-2-amino-5-(4-(2-(3,5-difluorophenyl)-2-hydroxyacetamido)-2-methylphenyl)-n-isopropylnicotinamide and methods for using the same |
| GB202407386D0 (en) | 2024-05-24 | 2024-07-10 | Apollo Ap45 Ltd | 1H-pyrazolo(4,3-D)pyrimidine derivatives |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| DK0970084T3 (da) | 1997-03-19 | 2003-09-29 | Abbott Gmbh & Co Kg | Pyrrolo[2,3-d]pyrimidiner og deres anvendelse som inhibitorer for tyrosinkinase |
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| TW200306819A (en) * | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| EP1501514B1 (en) * | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| EA010485B1 (ru) * | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
| WO2005030933A2 (en) | 2003-09-24 | 2005-04-07 | Genera Doo | Bone morphogenetic protein (bmp)-7 based diagnosis and treatment of cancer |
| PE20070335A1 (es) * | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| US8211919B2 (en) * | 2005-09-02 | 2012-07-03 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
| NZ617520A (en) | 2008-02-25 | 2015-05-29 | Nestec Sa | Drug selection for breast cancer therapy using antibody-based arrays |
| US20120014911A1 (en) | 2009-01-09 | 2012-01-19 | Serge Fuchs | Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor |
| CA2794153C (en) | 2010-03-25 | 2018-01-02 | Glaxosmithkline Llc | Substituted indoline derivatives as perk inhibitors |
| EP2986286A1 (en) | 2013-04-15 | 2016-02-24 | Universita' Degli Studi di Bari | Galloyl benzamide-based compounds as jnk modulators |
| WO2015056180A1 (en) | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Indoline derivatives as inhibitors of perk |
| WO2015068767A1 (ja) | 2013-11-08 | 2015-05-14 | 小野薬品工業株式会社 | ピロロピリミジン誘導体 |
| WO2015136463A1 (en) | 2014-03-11 | 2015-09-17 | Glaxosmithkline Intellectual Property (No.2) Limited | Chemical compounds acting as perk inhibitors |
| WO2016004254A1 (en) | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Combined modulation of ire1 |
| ES2792036T3 (es) | 2014-11-14 | 2020-11-06 | Nerviano Medical Sciences Srl | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de cinasa |
| GB201508747D0 (en) | 2015-05-21 | 2015-07-01 | Univ Edinburgh | Compounds |
| WO2017019442A1 (en) * | 2015-07-24 | 2017-02-02 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to kit and pdgfr |
| CN109153680B (zh) | 2016-07-07 | 2021-04-23 | 株式会社大熊制药 | 4-氨基吡唑并[3,4-d]嘧啶基氮杂双环衍生物及含其的药物组合物 |
| JP2019521166A (ja) | 2016-07-20 | 2019-07-25 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｐｅｒｋ阻害剤としてのイソキノリン誘導体 |
| CN106748989B (zh) | 2016-11-14 | 2020-03-17 | 西安交通大学 | 一种具有抗肿瘤活性的二芳基脲类化合物及其制备方法和应用 |
| US20190388426A1 (en) | 2017-01-30 | 2019-12-26 | Université de Liège | Perk and ire-1a inhibitors against neurodevelopmental disorders |
| PL4039675T3 (pl) | 2017-04-18 | 2025-01-07 | Eli Lilly And Company | Związki fenylo-2-hydroksyacetyloamino-2-metylo-fenylowe |
| JP7304855B2 (ja) | 2017-11-14 | 2023-07-07 | ザ チルドレンズ メディカル センター コーポレーション | 新規イミダゾピリミジン化合物およびそれらの使用 |
| EP3492454A1 (en) | 2017-11-30 | 2019-06-05 | Step Pharma S.A.S. | Compounds |
| US20210121527A1 (en) | 2018-03-26 | 2021-04-29 | Icahn School Of Medicine At Mount Sinai | Methods of treating minimal residual cancer |
| US11186579B2 (en) | 2018-07-06 | 2021-11-30 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| US20220040183A1 (en) | 2018-10-01 | 2022-02-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of inhibitors of stress granule formation for targeting the regulation of immune responses |
-
2018
- 2018-04-11 PL PL21211015.9T patent/PL4039675T3/pl unknown
- 2018-04-11 CN CN202310753648.5A patent/CN117510405A/zh active Pending
- 2018-04-11 JP JP2019556703A patent/JP7110232B2/ja active Active
- 2018-04-11 KR KR1020197033523A patent/KR102575246B1/ko active Active
- 2018-04-11 DK DK21211015.9T patent/DK4039675T3/da active
- 2018-04-11 SI SI201831149T patent/SI4039675T1/sl unknown
- 2018-04-11 LT LTEPPCT/US2018/027005T patent/LT3612519T/lt unknown
- 2018-04-11 WO PCT/US2018/027005 patent/WO2018194885A1/en not_active Ceased
- 2018-04-11 PL PL18718570T patent/PL3612519T3/pl unknown
- 2018-04-11 PH PH1/2019/502363A patent/PH12019502363B1/en unknown
- 2018-04-11 HU HUE18718570A patent/HUE057745T2/hu unknown
- 2018-04-11 KR KR1020237029674A patent/KR20230129627A/ko not_active Ceased
- 2018-04-11 SM SM20240357T patent/SMT202400357T1/it unknown
- 2018-04-11 HU HUE21211015A patent/HUE068023T2/hu unknown
- 2018-04-11 EP EP21211015.9A patent/EP4039675B1/en active Active
- 2018-04-11 PT PT212110159T patent/PT4039675T/pt unknown
- 2018-04-11 MX MX2019012428A patent/MX389724B/es unknown
- 2018-04-11 FI FIEP21211015.9T patent/FI4039675T3/fi active
- 2018-04-11 CR CR20190519A patent/CR20190519A/es unknown
- 2018-04-11 US US16/606,410 patent/US11655214B2/en active Active
- 2018-04-11 ES ES21211015T patent/ES2988739T3/es active Active
- 2018-04-11 DK DK18718570.7T patent/DK3612519T3/da active
- 2018-04-11 SG SG11201909680U patent/SG11201909680UA/en unknown
- 2018-04-11 RS RS20240950A patent/RS65914B1/sr unknown
- 2018-04-11 ES ES18718570T patent/ES2906847T3/es active Active
- 2018-04-11 RS RS20220154A patent/RS62933B1/sr unknown
- 2018-04-11 LT LTEP21211015.9T patent/LT4039675T/lt unknown
- 2018-04-11 SI SI201830572T patent/SI3612519T1/sl unknown
- 2018-04-11 HR HRP20220263TT patent/HRP20220263T1/hr unknown
- 2018-04-11 CN CN201880033126.5A patent/CN110831927B/zh active Active
- 2018-04-11 AU AU2018255191A patent/AU2018255191B2/en active Active
- 2018-04-11 BR BR112019021867-0A patent/BR112019021867A2/pt not_active Application Discontinuation
- 2018-04-11 NZ NZ758291A patent/NZ758291A/en unknown
- 2018-04-11 EP EP18718570.7A patent/EP3612519B1/en active Active
- 2018-04-11 HR HRP20241188TT patent/HRP20241188T1/hr unknown
- 2018-04-11 MY MYPI2019006116A patent/MY199442A/en unknown
- 2018-04-11 PT PT187185707T patent/PT3612519T/pt unknown
- 2018-04-11 SM SM20220100T patent/SMT202200100T1/it unknown
-
2019
- 2019-10-16 ZA ZA2019/06811A patent/ZA201906811B/en unknown
- 2019-10-17 IL IL270005A patent/IL270005B/en unknown
- 2019-10-17 MX MX2022001310A patent/MX2022001310A/es unknown
- 2019-10-17 SA SA519410320A patent/SA519410320B1/ar unknown
- 2019-11-15 CO CONC2019/0012767A patent/CO2019012767A2/es unknown
-
2021
- 2021-12-09 IL IL288822A patent/IL288822B2/en unknown
-
2022
- 2022-03-01 CY CY20221100173T patent/CY1125150T1/el unknown
- 2022-07-18 AU AU2022206702A patent/AU2022206702B2/en active Active
- 2022-07-20 JP JP2022115300A patent/JP7331212B2/ja active Active
-
2023
- 2023-04-13 US US18/300,237 patent/US12590064B2/en active Active